ABG
CLYM

Ally Bridge Group’s Climb Bio CLYM Stock Holding History

Ally Bridge Group’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.25M Buy
+249,172
New +$2.57M 2.87% 10
2025
Q1 		– Sell
-760,225
Closed -$1.37M – 33
2024
Q4 		$1.37M Sell
760,225
-469,067
-38% -$1.7M 1.17% 30
2024
Q3 		$6.26M Buy
1,229,292
+729,292
+146% +$5.16M 3.35% 13
2024
Q2 		$3.56M Buy
+500,000
New +$3.33M 2.12% 24

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ally Bridge Group's CLYM Position: Q2 2026 in Review

Ally Bridge Group opened a new position in Climb Bio (CLYM) in Q2 2026: 249,172 shares worth $3.25M. The stake represents 2.87% of the portfolio and ranks #10 among its holdings. This is a return to the name: Ally Bridge Group previously reported a position in CLYM as recently as Q4 2024.

Ally Bridge Group first reported a position in CLYM in Q2 2024 and has held it in 4 quarters since. The position peaked at $6.26M in Q3 2024. 109 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

  • Ally Bridge Group held 249,172 shares of Climb Bio worth $3.25M as of Q2 2026.
  • Climb Bio was a new Ally Bridge Group position in Q2 2026.
  • Climb Bio made up 2.87% of Ally Bridge Group's portfolio in Q2 2026, its #10 holding.
  • Ally Bridge Group first reported a position in Climb Bio in Q2 2024 and has held it in 4 quarters since.
  • Ally Bridge Group's Climb Bio position peaked at $6.26M in Q3 2024.
  • 109 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on Ally Bridge Group's 13F filing for Q2 2026, filed 14 Aug 2026.